サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758161

糖尿病性ケトアシドーシスの世界市場

Diabetic Ketoacidosis

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
糖尿病性ケトアシドーシスの世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

糖尿病性ケトアシドーシスの世界市場は2030年までに38億米ドルに達する見込み

2024年に31億米ドルと推定される糖尿病性ケトアシドーシスの世界市場は、2024～2030年の分析期間においてCAGR 3.4%で成長し、2030年には38億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるインスリン治療薬は、CAGR 2.9%を記録し、分析期間終了時には20億米ドルに達すると予測されます。電解質補充治療セグメントの成長率は、分析期間中CAGR 3.8%と推定されます。

米国市場は8億5,630万米ドルと推定、中国はCAGR6.2％で成長予測

米国の糖尿病性ケトアシドーシス市場は、2024年に8億5,630万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.2％を引きずる形で、2030年までに7億5,660万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3%と2.6%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界の糖尿病性ケトアシドーシス治療薬市場- 主要動向と促進要因のまとめ

なぜ糖尿病性ケトアシドーシスは糖尿病治療においてますます重要な焦点になりつつあるのか？

糖尿病性ケトアシドーシス（DKA）は、生命を脅かす重篤な糖尿病の急性合併症であり、主に1型糖尿病患者や、最近では管理不十分な2型糖尿病患者が罹患しています。DKAはインスリン欠乏により発症し、脂肪の過剰分解、ケトン体産生、代謝性アシドーシスを引き起こします。DKAは多くの場合、インスリンの投与漏れ、感染症、外傷、あるいは糖尿病の未診断から生じ、未治療の場合、急速に昏睡や死に至ることがあります。世界の糖尿病罹患率の増加、特に若年層や十分な治療を受けていない人々の増加に伴い、DKAエピソードの頻度とヘルスケア負担も増加しています。

インスリン依存症の患者数が増加していることに加え、中低所得国では継続的な血糖モニタリングや時宜を得た介入へのアクセスが限られているため、DKAの管理は糖尿病の救急および慢性治療における最優先課題となっています。さらに、2型糖尿病におけるSGLT2阻害薬の使用増加により、著明な高血糖を伴わずにケトアシドーシスが発症する「優血糖性DKA」のリスクが導入され、早期発見と鑑別がより困難になっています。このようなリスクプロファイルの進展により、医療機関は入院・外来を問わず、より広範なスクリーニングと治療プロトコルの導入を迫られています。

DKAを管理するための主要な治療戦略と臨床プロトコールとは？

DKAの治療は、インスリン静注、輸液蘇生、電解質補正（特にカリウム）、および根本的な誘因の同定と解決を含む、確立されたプロトコールが中心です。等張食塩水の即時投与は循環量の回復に役立ち、一方、インスリン療法はケト新生を停止させ、高血糖を徐々に減少させる。インスリン療法ではカリウムが細胞内に取り込まれるため、注意深く監視しないとしばしば危険な低カリウム血症に至るので、カリウムの補給は極めて重要です。重篤な症例では、重炭酸塩療法が重度のアシドーシスを是正するために使用されることがあるが、その使用は極度のpH異常の場合に限られます。

ベッドサイドでの迅速な血中ケトン測定、動脈血ガス分析、血中グルコースと電解質レベルの継続的モニタリングは、急性DKA管理に不可欠な要素です。病院の救急部や集中治療室には、中等度から重度のDKA患者をトリアージし、安定化させるためのプロトコールが一般的に備えられています。回復後の患者は、再発予防のために、構造化されたインスリンレジメンの調整、シックデイのルールに関する教育、グルコースモニタリングへのアクセス改善が必要です。このような全身的なアプローチには、内分泌専門医、救急医療提供者、糖尿病教育者、重症治療専門医の協力が必要です。

技術と診断の進歩はDKA管理と予防をどのように強化しているか？

糖尿病治療における技術革新は、DKAの早期発見と管理を著しく向上させています。持続グルコースモニタリング（CGM）システム、自動懸濁機能付きインスリンポンプ、リアルタイムアラート機能付きモバイルアプリは、患者が重篤な脱血を起こす前に代謝の変化を発見するのに役立っています。血中ケトン体測定器は、現在では家庭用として広く普及しており、病気やインスリン中断時の早期診断が可能となり、入院や長期合併症の減少につながっています。

ヘルスケアプロバイダーは、特に感染症、手術、薬物不遵守による入院中に、DKAのリスクが高い患者にフラグを立てるために、電子カルテの予測分析を活用するようになってきています。遠隔医療サービスと統合された教育プラットフォームは、インスリンのアドヒアランス、栄養計画、疾病時の早期介入をサポートすることで、DKAを予防する役割が高まっています。遠隔糖尿病ケアと構造化された退院計画の拡大は、患者の長期的転帰を向上させ、再発率を低下させています。

糖尿病性ケトアシドーシス治療薬市場の成長を促進する主な要因は？

糖尿病性ケトアシドーシス治療薬市場の成長は、インスリン依存性糖尿病の世界の有病率の上昇、急性糖尿病合併症による入院率の増加、構造化された救急医療プロトコルの利用可能性の拡大など、いくつかの要因によってもたらされます。ヘルスケアシステムは、特に都市部の病院や救急ネットワークにおいて、より広範な糖尿病治療の取り組みの一環としてDKAの検出・管理インフラに投資しています。ケトン体モニタリングが日常的な糖尿病管理に組み込まれ、SGLT2阻害薬使用者における高血糖性DKAのような非典型的なDKA症状に対する認識が高まっていることも、診断・治療ツールに対する需要を促進しています。

市場の成長は、インスリンデリバリー、グルコースおよびケトン体モニタリングデバイス、クリティカルケア用高度輸液管理システムなどの技術革新によってさらに支えられています。教育普及活動、インスリン治療へのアクセス改善、個別化された患者支援は、早期介入とフォローアップの障壁を減らしています。これと並行して、製薬企業やデバイス企業は、DKAの再発を予防するために、ハイリスク患者向けの統合ケアソリューションを開発しています。急性糖尿病合併症に対処するためのヘルスケア政策とデジタル技術の連携が進むにつれて、糖尿病性ケトアシドーシス治療薬市場は先進地域と新興地域の両方で着実に拡大すると予想されます。

セグメント

治療薬（インスリン治療薬、電解質補充治療薬、輸液補充治療薬）;エンドユース（病院・診療所エンドユース、外来手術センターエンドユース、その他エンドユース）

調査対象企業の例（注目の合計42社）

  • Abbott Laboratories
  • Akums Drugs and Pharmaceuticals
  • AstraZeneca
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dexcom Inc.
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals
  • Glytec
  • Johnson & Johnson
  • Medtronic plc
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Panacea Biotec
  • Pfizer Inc.
  • Sanofi S.A.
  • Wockhardt Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36694

Global Diabetic Ketoacidosis Market to Reach US$3.8 Billion by 2030

The global market for Diabetic Ketoacidosis estimated at US$3.1 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Insulin Therapy Treatment, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Electrolyte Replacement Treatment segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$856.3 Million While China is Forecast to Grow at 6.2% CAGR

The Diabetic Ketoacidosis market in the U.S. is estimated at US$856.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$756.6 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Diabetic Ketoacidosis Therapeutics Market - Key Trends & Drivers Summarized

Why Is Diabetic Ketoacidosis Becoming an Increasingly Critical Focus in Diabetes Care?

Diabetic ketoacidosis (DKA) is a serious, life-threatening acute complication of diabetes mellitus, predominantly affecting patients with type 1 diabetes and, increasingly, those with poorly managed type 2 diabetes. It occurs due to insulin deficiency, leading to excessive fat breakdown, ketone production, and metabolic acidosis. DKA often arises from missed insulin doses, infections, trauma, or undiagnosed diabetes, and if untreated, can rapidly progress to coma or death. As global diabetes prevalence rises-especially among younger and underserved populations-the frequency and healthcare burden of DKA episodes are also escalating.

The growing number of insulin-dependent individuals, combined with limited access to continuous glucose monitoring and timely interventions in low- and middle-income countries, has made DKA management a high-priority focus in emergency and chronic diabetes care. Furthermore, increased use of SGLT2 inhibitors in type 2 diabetes has introduced a risk of “euglycemic DKA,” where ketoacidosis develops without significant hyperglycemia, making early detection and differentiation more challenging. This evolving risk profile is pushing providers to implement broader screening and treatment protocols in both inpatient and outpatient settings.

What Are the Key Therapeutic Strategies and Clinical Protocols for Managing DKA?

Treatment of DKA is centered on a well-established protocol involving intravenous insulin infusion, fluid resuscitation, electrolyte correction (especially potassium), and identification and resolution of the underlying trigger. Immediate administration of isotonic saline helps restore circulatory volume, while insulin therapy halts ketogenesis and gradually reduces hyperglycemia. Potassium supplementation is critical, as insulin therapy drives potassium into cells, often leading to dangerous hypokalemia if not carefully monitored. In severe cases, bicarbonate therapy may be used to correct profound acidosis, although its use is reserved for extreme pH derangements.

Rapid bedside blood ketone measurement, arterial blood gas analysis, and continuous monitoring of blood glucose and electrolyte levels are essential components of acute DKA management. Hospital emergency departments and intensive care units are typically equipped with protocols for triaging and stabilizing patients with moderate to severe DKA. Post-recovery, patients require structured insulin regimen adjustment, education on sick-day rules, and improved access to glucose monitoring to prevent recurrence. This systemic approach involves collaboration among endocrinologists, emergency care providers, diabetes educators, and critical care specialists.

How Are Technological and Diagnostic Advances Enhancing DKA Management and Prevention?

Technological innovation in diabetes care is significantly improving the early detection and management of DKA. Continuous glucose monitoring (CGM) systems, insulin pumps with auto-suspend features, and mobile apps with real-time alerts are helping patients detect metabolic changes before severe decompensation occurs. Blood ketone meters-now widely available for at-home use-enable early diagnosis during illness or insulin interruption, reducing hospital admissions and long-term complications.

Healthcare providers are increasingly utilizing predictive analytics in electronic health records to flag patients at high risk of DKA, especially during hospital admissions for infections, surgeries, or medication non-compliance. Educational platforms integrated with telehealth services are playing a growing role in preventing DKA by supporting insulin adherence, nutritional planning, and early intervention during illness. The expansion of remote diabetes care and structured discharge planning is enhancing long-term patient outcomes and reducing recurrence rates.

What Are the Key Drivers Propelling Growth in the Diabetic Ketoacidosis Therapeutics Market?

The growth in the diabetic ketoacidosis therapeutics market is driven by several factors, including the rising global prevalence of insulin-dependent diabetes, increased hospitalization rates for acute diabetic complications, and expanding availability of structured emergency care protocols. Healthcare systems are investing in DKA detection and management infrastructure as part of broader diabetes care initiatives, especially in urban hospitals and emergency networks. The integration of ketone monitoring into routine diabetes management and the growing awareness of atypical DKA presentations-such as euglycemic DKA in SGLT2 inhibitor users-are also fueling demand for diagnostic and therapeutic tools.

Market growth is further supported by innovation in insulin delivery, glucose and ketone monitoring devices, and advanced fluid management systems for critical care. Educational outreach, improved access to insulin therapy, and personalized patient support are reducing barriers to early intervention and follow-up. In parallel, pharmaceutical and device companies are developing integrated care solutions for high-risk patients to prevent recurrent DKA events. As healthcare policies and digital technologies align to address acute diabetes complications, the diabetic ketoacidosis therapeutics market is expected to expand steadily across both developed and emerging regions.

SCOPE OF STUDY:

The report analyzes the Diabetic Ketoacidosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Insulin Therapy Treatment, Electrolyte Replacement Treatment, Fluid Replacement Treatment); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Akums Drugs and Pharmaceuticals
  • AstraZeneca
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dexcom Inc.
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals
  • Glytec
  • Johnson & Johnson
  • Medtronic plc
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Panacea Biotec
  • Pfizer Inc.
  • Sanofi S.A.
  • Wockhardt Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Diabetic Ketoacidosis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Type 1 and Uncontrolled Type 2 Diabetes Propels Risk of Diabetic Ketoacidosis (DKA)
    • Increased Hospitalization Rates for Hyperglycemic Emergencies Strengthen Demand for Acute DKA Management Protocols
    • Growing Awareness of DKA Symptoms Promotes Early Intervention and Reduces Mortality Risk
    • Expansion of Insulin Pump Therapy and CGM Use Throws the Spotlight on DKA Prevention Technologies
    • Clinical Integration of Point-of-Care Ketone Testing Devices Improves Rapid Diagnosis in Emergency Departments
    • AI-Based Glucose Monitoring Alerts Enhance Early DKA Risk Detection in Home-Care Settings
    • Adoption of Standardized Emergency DKA Protocols Across Hospitals Supports Timely Electrolyte Correction
    • Growth in Pediatric Diabetes Diagnoses Fuels Demand for Child-Specific DKA Treatment Guidelines
    • Rising Awareness Among Primary Care Physicians Supports Timely DKA Referral and Hospitalization
    • Expansion of Tele-Endocrinology Improves Access to Preventive Care in DKA-Prone Patients
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Diabetic Ketoacidosis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Diabetic Ketoacidosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Insulin Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Insulin Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Insulin Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Electrolyte Replacement Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Electrolyte Replacement Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Electrolyte Replacement Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Fluid Replacement Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Fluid Replacement Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Fluid Replacement Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Diabetic Ketoacidosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Diabetic Ketoacidosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Diabetic Ketoacidosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Diabetic Ketoacidosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Diabetic Ketoacidosis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Diabetic Ketoacidosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Diabetic Ketoacidosis by Treatment - Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Diabetic Ketoacidosis by Treatment - Percentage Breakdown of Value Sales for Insulin Therapy Treatment, Electrolyte Replacement Treatment and Fluid Replacement Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Diabetic Ketoacidosis by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Diabetic Ketoacidosis by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION